EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Phase 2 randomized study of abobotulinumtoxinA in patients with provoked vestibulodynia: dose-finding results

Andrew Goldstein, Rachel Rubin, Melissa Dahir, Irwin Goldstein, Brooke M Faught, Nina Bohm-Starke, Jill Krapf iD, Peter Caetano, Magali Volteau, Robert Silva

The Journal of Sexual Medicine · 2025

DOI: 10.1093/jsxmed/qdaf022 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Andrew Goldstein und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Centers for Vulvovaginal Disorders, Washington, DC 20037, United States. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Neuromuscular Agents, Vulvodynia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypertonicity of the pelvic floor muscles is commonly associated with provoked vestibulodynia (PVD); therefore, patients may benefit from treatments that relax the pelvic floor.

Aim

To define optimal (safe and efficacious) doses of abobotulinumtoxinA (aboBoNT-A) for the treatment of PVD associated with hypertonic pelvic floor muscle dysfunction and to explore use of a novel endpoint for pain assessment for PVD.

Methods

This phase 2, randomized, placebo-controlled study comprised two steps: dose escalation (Stage 1) and dose expansion (Stage 2). Stage 1 included up to four treatment cycles; Cycle 1 was double blind, Cycles 2–4 open label. Patients were assessed for retreatment every 6 weeks. Stage 2 was not conducted because of early study termination by the sponsor, unrelated to observed safety signals. Enrolled patients—premenopausal women with PVD with associated pelvic-floor hypertonia—were randomized (n = 60) 4:1 to receive aboBoNT-A (doses: 100, 300, 400, or 500 units [U]) or placebo. Outcomes The primary endpoint was safety. Additionally, a novel composite endpoint, dilator maximum tested size was evaluated. This endpoint combined assessment of vaginal-dilator tolerability with patient-reported pain assessment on an 11-point numeric rating scale, used as a surrogate measure of sexual activity in this study.

Results

All treatment-emergent adverse events (AEs) were mild or moderate in intensity, with no serious AEs or AEs leading to withdrawal reported in the double-blind period. AEs of special interest (urinary incontinence, anal sphincter atonia) were observed at low incidence and predominantly with higher aboBoNT-A doses. The dilator test composite score might be a useful endpoint for pain assessment, with a greater reduction in pain score noted for the 300 U dose group compared with other dose groups and placebo. Clinical implications aboBoNT-A was well tolerated in patients with PVD and a novel method for assessing dilator-induced pain was introduced. Strengths and limitations The study provided valuable data on use of aboBoNT-A in women with primary or secondary PVD and introduced a novel composite endpoint for assessing dilator-induced pain. Study limitations included the small sample size, limiting formal statistical analysis. Conclusion aboBoNT-A was well tolerated in patients with PVD with no safety signals reported. Further studies are warranted to demonstrate clinically meaningful benefits with repeated treatment. Clinical trial registration number NCT03598777.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ANeuromuscular AgentsVulvodyniaAdultFemaleHumansMiddle AgedDose-Response Relationship, DrugDouble-Blind MethodPain MeasurementTreatment Outcome

Stichwörter der Autor:innen

abobotulinumtoxinAfemale medicalfemale sexual dysfunctionnovel efficacy endpointpatient-reported painpelvic floor disorders and therapyprovoked vestibulodyniasexual painvulvodynia

Substanzen

abobotulinumtoxinABotulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • The Centers for Vulvovaginal Disorders, Washington, DC 20037, United States.
  • Georgetown University, Department of Urology Washington, DC 20057, United States.
  • Embody Medicine, Omaha, NE 68130, United States.
  • San Diego Sexual Medicine, San Diego, CA 92120, United States.
  • PazonaMD Urology, Brentwood, TN 37209, United States.
  • Department of Clinical Sciences, Division of Obstetrics and Gynecology, Karolinska Institutet Danderyd Hospital, 3 Washington Circle NW, Suite 205, Stockholm, Sweden.

ORCID-Profile: Jill Krapf

Zitieren

APA

Goldstein, A., Rubin, R., Dahir, M., Goldstein, I., Faught, B. M., Bohm-Starke, N., Krapf, J., Caetano, P., Volteau, M., & Silva, R. (2025). Phase 2 randomized study of abobotulinumtoxinA in patients with provoked vestibulodynia: dose-finding results. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf022

Vancouver

Goldstein A, Rubin R, Dahir M, Goldstein I, Faught BM, Bohm-Starke N, et al. Phase 2 randomized study of abobotulinumtoxinA in patients with provoked vestibulodynia: dose-finding results. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdaf022

BibTeX
@article{Goldstein2025,
  author = {Goldstein, Andrew and Rubin, Rachel and Dahir, Melissa and Goldstein, Irwin and Faught, Brooke M and Bohm-Starke, Nina and Krapf, Jill and Caetano, Peter and Volteau, Magali and Silva, Robert},
  title = {Phase 2 randomized study of abobotulinumtoxinA in patients with provoked vestibulodynia: dose-finding results},
  journal = {The Journal of Sexual Medicine},
  year = {2025},
  doi = {10.1093/jsxmed/qdaf022}
}
Kostenlos starten →